Clinical Trial Update: Assessment of Safety and Immunogenicity of R21/Matrix-M™ in African Children Living With HIV [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and immunogenicity of the malaria vaccine candidate R21/Matrix-M in African children living with HIV has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• R21/Matrix-M

Snippet

Sponsor: University of Oxford | Conditions: Malaria | Phase 1 | Status: COMPLETED